# reload+after+2024-01-20 06:45:05.928881
address1§611 Gateway Boulevard
address2§Suite 223
city§South San Francisco
state§CA
zip§94080
country§United States
phone§628 229 9277
website§https://structuretx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
fullTimeEmployees§87
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Raymond C. Stevens Ph.D.', 'age': 59, 'title': 'CEO & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 747333, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Yingli  Ma Ph.D.', 'age': 49, 'title': 'Chief Technology Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 497585, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark A. Bach M.D., Ph.D.', 'age': 66, 'title': 'Chief Medical Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 628374, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jun S. Yoon', 'age': 45, 'title': 'Co- Founder, CFO & Secretary', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Xichen  Lin Ph.D.', 'age': 49, 'title': 'Chief Scientific Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Tony  Peng', 'title': 'Senior Vice President of Legal', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bob  Gatmaitan', 'title': 'Senior Vice President of People', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Hui  Lei Ph.D.', 'title': 'Senior Vice President of Chemistry', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Fang  Zhang Ph.D.', 'title': 'Executive VP & Head of Biology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lani  Ibarra', 'title': 'Senior Vice President of Clinical Development Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
currency§USD
dateShortInterest§1702598400
forwardEps§-0.99
exchange§NGM
quoteType§EQUITY
shortName§Structure Therapeutics Inc.
longName§Structure Therapeutics Inc.
firstTradeDateEpochUtc§1675434600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§8fb71ef4-0d7a-30de-b9f4-2631f9206cd7
gmtOffSetMilliseconds§-18000000
targetHighPrice§93.0
targetLowPrice§58.0
targetMeanPrice§82.67
targetMedianPrice§87.0
recommendationMean§1.5
recommendationKey§strong_buy
numberOfAnalystOpinions§6
quickRatio§10.225
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
